News

Cirencester, UK, April 30th, 2024 — OBS Medical announced today that Health Canada has authorised the use of Visensia® to aid in the early recognition and response to clinical deterioration for in hospital patients. OBS Medical continues its mission to promote the use of continuous vital sign monitoring integrated with an Early Warning System (EWS) […]

As part of the partnership, OBS Medical will assist TMS to commercially develop three novel variability-derived clinical decision support software products and to gain necessary regulatory approvals. The first Clinical Decision Support System (CDSS) in this suite of predictive analytics will be Extubation Advisor (EA).

Managing Director Simon Didcote explains, “To market Visensia in Japan has been a long-term ambition of OBS Medical. The need to identify and prioritize patients who are unstable or showing early signs of deterioration in the era of the COVID pandemic has never been greater.”

Partnering with Nihon Kohden on this endeavour has been very rewarding in terms of their expertise and knowledge in advanced digital technology driven by data, as well as their mutual understanding of the clinical need for Visensia”. Now that we have market approval, we can begin to evidence the health economic benefits the technology enables, helping to drive adoption across the region.

QardioMD+VSI is a remote monitoring solution that combines the data from Qardio’s range of award winning and medically accurate wearables, with the Visensia® predictive algorithm. This combination allows Clinicians to remotely review a patients’ vital signs in real time and to prioritise those patients according to the Visensia risk stratification algorithm – Visensia Safety Index (VSI).